In the SPS3 trial , patients with recent ( within 6 months ) symptomatic lacunar infarcts from 81 centres in North America , Latin America , and Spain were randomly assigned , in a two-by-two factorial design , to target levels of systolic blood pressure ( 1:1 ; 130-149 mm Hg vs < 130 mm Hg ; open-label ) and to a once-daily antiplatelet treatment ( 1:1 ; aspirin 325 mg plus clopidogrel 75 mg vs aspirin 325 mg plus placebo ; double-blind ) .